Endocrine therapy for gynecological cancer (Q33843872)

29 July 2017

1 reference

title

Endocrine therapy for gynecological cancer (English)

1 reference

29 July 2017

Gadducci A

1

1 reference

29 July 2017

Genazzani AR

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Gynecological Endocrinology

29 July 2017

published in

1 reference

29 July 2017

volume

13

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

441-456

1 reference

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Clinical potential of new antiestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513599909167590

10.3109/09513599909167590

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference